



Contents lists available at [ScienceDirect](http://www.sciencedirect.com)

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Corrigendum

Corrigendum to “N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: Impact of small structural modifications on P-gp recognition and CNS penetration” [Bioorg. Med. Chem. Lett. 19 (2009) 5078]

Florian Wakenhut^{a,*}, Gill A. Allan^c, Paul V. Fish^a, M. Jonathan Fray^a, Anthony C. Harrison^c, Rachel McCoy^b, Stephen C. Phillips^b, Thomas Ryckmans^a, Alan Stobie^a, Dominique Westbrook^b, Simon L. Westbrook^b, Gavin A. Whitlock^a

^a Department of Genitourinary Chemistry, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK

^b Department of Genitourinary Biology, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK

^c Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK

The name of Thomas Ryckmans was inadvertently omitted from the author line. The correct author line appears above.

DOI of original article: [10.1016/j.bmcl.2009.07.049](https://doi.org/10.1016/j.bmcl.2009.07.049).

* Corresponding author. Tel.: +44 1304 640950; fax: +44 1304 651987.

E-mail address: florian.wakenhut@pfizer.com (F. Wakenhut).